The study team will determine the association between d,l-methylphenidate (MPH) therapeutic outcomes in ADHD patients and genetic variants of CES1 and reveal key associations between CES1 genotypes and the PK and PD of MPH.
ADHD, Attention Deficit Hyperactivity Disorder
The study team will determine the association between d,l-methylphenidate (MPH) therapeutic outcomes in ADHD patients and genetic variants of CES1 and reveal key associations between CES1 genotypes and the PK and PD of MPH.
Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD
-
University of Florida, Gainesville, Florida, United States, 32610
Icahn School of Medicine at Mount Sinai, New York, New York, United States, 10029
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, 45229
Seattle Children's Hospital, Seattle, Washington, United States, 98105
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
6 Years to 17 Years
ALL
No
Icahn School of Medicine at Mount Sinai,
Jeffrey Newcorn, MD, PRINCIPAL_INVESTIGATOR, Icahn School of Medicine at Mount Sinai
Mark Stein, PhD, PRINCIPAL_INVESTIGATOR, University of Washington
Tanya Froehlich, MD, PRINCIPAL_INVESTIGATOR, Children's Hospital Medical Center, Cincinnati
2025-08